US2021252024A1PendingUtilityA1

Cancer Drug and Uses

Assignee: HEALTH CLINICS LTDPriority: Jan 14, 2013Filed: May 5, 2021Published: Aug 19, 2021

Est. expiryJan 14, 2033(~6.5 yrs left)· nominal 20-yr term from priority

Inventors:Robin M. Bannister John Brew Gregory Alan Stoloff

A61K 31/05A61K 31/352Y02A50/30A61K 9/4858A61K 31/19A61K 31/225A61K 31/40A23L 33/10A61K 39/39558A61K 31/59A61K 31/7068A61K 31/4184A61K 31/375A61K 9/48A61K 31/353A61K 31/357A61K 31/517A61K 31/155A61P 35/00A61K 31/366A61P 35/02

PatentIndex Score

Cited by

References

Claims

Abstract

A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical kit comprising a biguanide, a statin, and a benzimidazole. 
     
     
         2 . The pharmaceutical kit according to  claim 1 , wherein the biguanide is a metformin, a phenformin, a buformin, or any combination thereof. 
     
     
         3 . The pharmaceutical kit according to  claim 1 , wherein the biguanide is a metformin. 
     
     
         4 . The pharmaceutical kit according to  claim 1 , wherein the statin is an atorvastatin, a fluvastin, a lovastatin, a pitavastatin, a pravastatin, a rosuvastatin, a simvastatin, or any combination thereof. 
     
     
         5 . The pharmaceutical kit according to  claim 1 , wherein the statin is an atorvastatin. 
     
     
         6 . The pharmaceutical kit according to  claim 3 , wherein the statin is an atorvastatin. 
     
     
         7 . The pharmaceutical kit according to  claim 1 , wherein the benzimidazole is an albendazole, a fenbendazole, a flubendazole, a thiabendazole, a triclabendazole, or any combination thereof. 
     
     
         8 . The pharmaceutical kit according to  claim 7 , wherein the flubendazole is a mebendazole. 
     
     
         9 . The pharmaceutical kit according to  claim 1 , wherein the benzimidazole is a flubendazole. 
     
     
         10 . The pharmaceutical kit according to  claim 9 , wherein the flubendazole is a mebendazole. 
     
     
         11 . The pharmaceutical kit according to  claim 6 , wherein the benzimidazole is a mebendazole. 
     
     
         12 . The pharmaceutical kit according to  claim 11 , further comprising a doxycycline. 
     
     
         13 . A pharmaceutical kit comprising a biguanide, a statin, and a cytotoxic antibiotic. 
     
     
         14 . The pharmaceutical kit according to  claim 13 , wherein the biguanide is a metformin, a phenformin, a buformin, or any combination thereof. 
     
     
         15 . The pharmaceutical kit according to  claim 13 , wherein the biguanide is a metformin. 
     
     
         16 . The pharmaceutical kit according to  claim 13 , wherein the statin is an atorvastatin, a fluvastin, a lovastatin, a pitavastatin, a pravastatin, a rosuvastatin, a simvastatin, or any combination thereof. 
     
     
         17 . The pharmaceutical kit according to  claim 13 , wherein the statin is an atorvastatin. 
     
     
         18 . The pharmaceutical kit according to  claim 15 , wherein the statin is an atorvastatin. 
     
     
         19 . The pharmaceutical kit according to  claim 13 , wherein the cytotoxic antibiotic is a doxycycline. 
     
     
         20 . The pharmaceutical kit according to  claim 18 , wherein the cytotoxic antibiotic is a doxycycline. 
     
     
         21 . The pharmaceutical kit according to  claim 20 , further comprising a mebendazole.

Join the waitlist — get patent alerts

Track US2021252024A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.